Skip to main content
. 2021 Oct 5;8(6):4465–4483. doi: 10.1002/ehf2.13595

Figure 1.

Figure 1

(A) Schematic representation of European HF guidelines and The American College of Cardiology guidelines regarding biomarkers coupled with classes of recommendations and level of evidence; (B) studies involving the biomarkers. AHF, acute heart failure; ADHERE, Acute Decompensated Heart Failure National Registry; ACC/AHA, American College of Cardiology/American Heart Association; BNP, B‐type or brain natriuretic peptide; CORONA, Controlled Rosuvastatin Multinational Trial in Heart Failure; COACH, Coordinating Study Evaluating Outcomes of Advising and Counselling Failure; ESC, European Society of Cardiology; Gal‐3, galectin‐3; HF, heart failure; NP, natriuretic peptides; N/A, not applicable; NT‐proBNP, N‐terminal pro B‐type natriuretic peptide; PRIDE study, Pro‐Brain Natriuretic Peptide Investigation of Dyspnoea in the Emergency Department; sST2, soluble suppression of tumourigenicity; RELAX‐AHF trial, Relaxin in Acute Heart Failure trial.